O
Outlook Therapeutics D
D
OTLK
1.44500
USD
-0.03
(-2.03%)
Post Trading·1.47500USD+0.03000(+2.08%)
حجم التداول
105,902
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
214,708,387
المقالات
العنوان: Outlook Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorizationfor an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.